These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 476980)

  • 1. Mineralocorticoid replacement in Addison's disease.
    Thompson DG; Mason AS; Goodwin FJ
    Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
    Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fludrocortisone withdrawal on plasma angiotensin II, ACTH, vasopressin, and potassium in patients with Addison's disease.
    Oelkers W; Bähr V
    Acta Endocrinol (Copenh); 1987 Jul; 115(3):325-30. PubMed ID: 3039766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that patients with Addison's disease are undertreated with fludrocortisone.
    Smith SJ; MacGregor GA; Markandu ND; Bayliss J; Banks RA; Prentice MG; Dorrington-Ward P; Wise P
    Lancet; 1984 Jan; 1(8367):11-4. PubMed ID: 6140341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement.
    Oelkers W; L'age M
    Klin Wochenschr; 1976 Jul; 54(13):607-12. PubMed ID: 940296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin, angiotensin, corticosteroids, and electrolyte balance in Addison's disease.
    Brown JJ; Fraser R; Lever AF; Robertson JI; James VH; McCusker J; Wynn V
    Q J Med; 1968 Jan; 37(145):97-118. PubMed ID: 4297956
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.
    Oelkers W; Diederich S; Bähr V
    J Clin Endocrinol Metab; 1992 Jul; 75(1):259-64. PubMed ID: 1320051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M; Gryczyńska M; Sowińska A; Sowiński J
    Przegl Lek; 2011; 68(2):96-102. PubMed ID: 21751518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency.
    Flad TM; Conway JD; Cunningham SK; McKenna TJ
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):529-34. PubMed ID: 8977748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible cardiomyopathy in paediatric Addison's disease--a cautionary tale.
    Conwell LS; Gray LM; Delbridge RG; Thomsett MJ; Batch JA
    J Pediatr Endocrinol Metab; 2003; 16(8):1191-5. PubMed ID: 14594181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
    Baumstark ME; Nussberger J; Boretti FS; Baumstark MW; Riond B; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2014; 28(5):1471-8. PubMed ID: 25274440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oedema in patients with Addison's disease on replacement therapy: glucocorticoid excess and mineralocorticoid deficiency?
    Flynn MD; Shore AC; Sandeman DE; Mawson D; Donohoe M; Tooke JE
    QJM; 1994 Jul; 87(7):437-41. PubMed ID: 7922296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium inhibits the action of fludrocortisone on the kidney.
    Stewart PM; Grieve J; Nairn IM; Padfield PL; Edwards CR
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):63-8. PubMed ID: 3115635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency.
    Quinkler M; Oelkers W; Remde H; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):17-24. PubMed ID: 25617169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Addison's disease and pregnancy].
    Gundersen T
    Tidsskr Nor Laegeforen; 1979 Jan; 99(2):87-8. PubMed ID: 419488
    [No Abstract]   [Full Text] [Related]  

  • 16. Addison's disease in pregnancy: Case report, management, and review of the literature.
    Margulies SL; Corrigan K; Bathgate S; Macri C
    J Neonatal Perinatal Med; 2020; 13(2):275-278. PubMed ID: 31744021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy and Addison's disease.
    Khunda S
    Obstet Gynecol; 1972 Mar; 39(3):431-4. PubMed ID: 5019317
    [No Abstract]   [Full Text] [Related]  

  • 18. Mineralocorticoids in the management of primary adrenocortical insufficiency.
    Jadoul M; Ferrant A; De Plaen JF; Crabbé J
    J Endocrinol Invest; 1991 Feb; 14(2):87-91. PubMed ID: 2061574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison's disease.
    Berardelli R; Karamouzis I; D'Angelo V; Fussotto B; Minetto MA; Ghigo E; Giordano R; Arvat E
    J Endocrinol Invest; 2016 May; 39(5):537-42. PubMed ID: 26450146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary pituitary hyperplasia in Addison's disease.
    Clayton R; Burden AC; Schrieber V; Rosenthal FD
    Lancet; 1977 Nov; 2(8045):954-6. PubMed ID: 72291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.